Lyra Therapeutics (NASDAQ:LYRA) Trading 6.2% Higher – Should You Buy?

Lyra Therapeutics, Inc. (NASDAQ:LYRA)’s stock price shot up 6.2% during mid-day trading on Tuesday . The company traded as high as $0.69 and last traded at $0.69. 1,377 shares traded hands during trading, a decline of 98% from the average session volume of 59,737 shares. The stock had previously closed at $0.65.

Lyra Therapeutics Stock Performance

The stock has a market cap of $1.21 million, a price-to-earnings ratio of -0.03 and a beta of 0.70. The business’s 50 day moving average is $0.70 and its 200-day moving average is $1.62.

Institutional Trading of Lyra Therapeutics

Several institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC acquired a new position in shares of Lyra Therapeutics during the 3rd quarter worth about $128,000. Bank of America Corp DE boosted its holdings in Lyra Therapeutics by 33.7% in the 2nd quarter. Bank of America Corp DE now owns 28,542 shares of the company’s stock worth $256,000 after buying an additional 7,190 shares during the last quarter. DRW Securities LLC acquired a new stake in Lyra Therapeutics in the 4th quarter worth about $52,000. Artia Global Partners LP purchased a new stake in Lyra Therapeutics during the 4th quarter worth approximately $27,000. Finally, Sabby Management LLC increased its stake in Lyra Therapeutics by 37.2% during the 4th quarter. Sabby Management LLC now owns 175,158 shares of the company’s stock worth $539,000 after buying an additional 47,534 shares in the last quarter. Institutional investors and hedge funds own 95.62% of the company’s stock.

About Lyra Therapeutics

Lyra Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted drug delivery therapies for diseases of the ear, nose and throat (ENT). Leveraging its proprietary Therapeutic Drug Delivery (TDD) platform, the company designs bioresorbable, steroid-eluting implants that provide sustained, localized release of medication directly to affected tissue. This approach aims to improve patient outcomes by reducing the need for repeated administration and minimizing systemic side effects.

The company’s lead product candidate, LYR-210, is an implantable matrix that delivers the corticosteroid mometasone furoate over several months to treat chronic rhinosinusitis (CRS).